Abstract A178: Role of tumor and host-derived HGF in drug resistance to EGFR inhibitors in EGFR activating mutation-positive lung cancer
Soji Kakiuchi(Tokushima Prefectural Central Hospital), Saburo Sone(Io Therapeutics (United States)), Koji Otsuka(Tokushima University), Yasuhiko Nishioka(Tokushima University), Yasushi Yatabe(University Hospital Münster), Tetsuya Mitsudomi(Kindai University), Kunio Matsumoto(Kanazawa University), Qi Li, Wei Wang(Nanfang Hospital), Masaki Hanibuchi(Tokushima University), Takuya Kuramoto(Tokushima University), Tadaaki Yamada(Kyoto Prefectural University of Medicine), Seiji Yano(Kanazawa University Hospital)
Cited by 0
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Reduced Expression of the <b> <i>let-7</i> </b> MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival
|Cancer Research|2004|2.4k